Simpson Ian D, Norris Robert L
Wilderness Environ Med. 2007 Fall;18(3):163-8. doi: 10.1580/07-WEME-ED-099R.1.
Venomous snakebite continues to exact a tremendous toll in human suffering and mortality in India. Contributing to this problem is the fact that all of the current Indian snake antivenom manufacturers include a great deal of misinformation in the package inserts and guidelines that accompany their products. Examples include erroneous recommendations regarding first aid, misleading information regarding the signs and symptoms to be anticipated after Indian snakebite, and misleading and ambiguous recommendations as to initial dosing and repeat dosing of antivenom. In addition, the significant problem of acute adverse reactions to Indian antivenoms is compounded by a lack of appropriate recommendations regarding prevention, diagnosis, and management of such reactions. It is the intent of this article to point out problems with the current Indian antivenom product guidelines and to encourage these manufacturers to produce new literature to accompany their products based on the best available evidence.
在印度,毒蛇咬伤继续给人类带来巨大痛苦并造成极高死亡率。造成这一问题的原因是,目前所有印度蛇毒抗血清制造商在其产品附带的包装说明书和指南中都包含大量错误信息。例如,关于急救的错误建议、关于印度毒蛇咬伤后预期体征和症状的误导性信息,以及关于抗血清初始剂量和重复剂量的误导性和含糊不清的建议。此外,印度抗血清急性不良反应这一重大问题因缺乏关于此类反应的预防、诊断和管理的适当建议而更加严重。本文旨在指出当前印度抗血清产品指南存在的问题,并鼓励这些制造商根据现有最佳证据编写新的产品说明书。